COMPARISON: CAGRILINTIDE vs SEMAGLUTIDE
Cagrilintide vs Semaglutide: What's Different
Amylin pathway vs GLP-1 pathway
Cagrilintide vs semaglutide is a useful comparison because they target appetite through different hormone pathways — and are often studied together as CagriSema.
At a Glance
| Cagrilintide | Semaglutide | |
|---|---|---|
| Class | Amylin analog | GLP-1 receptor agonist |
| Pathway | Amylin/calcitonin receptors | GLP-1 receptor |
| Approval | Investigational (not approved) | FDA-approved (Ozempic, Wegovy) |
| Studied together? | Yes — as CagriSema | Yes — as CagriSema |
| Common effects | Mostly GI (trials) | Mostly GI |
Two Different Appetite Pathways
Semaglutide is a GLP-1 receptor agonist and is FDA-approved. Cagrilintide is an amylin analog and is investigational. Because the pathways differ but are complementary, the two are studied together as CagriSema.
Source: FDA labeling for semaglutide products; Novo Nordisk cagrilintide program reporting.
The Key Status Difference
The most important practical difference today is approval: semaglutide is approved, cagrilintide is not.
Frequently Asked Questions
Is cagrilintide a GLP-1 like semaglutide?
No. Cagrilintide is an amylin analog; semaglutide is a GLP-1 receptor agonist.
Is cagrilintide approved like semaglutide?
No. Semaglutide is approved; cagrilintide is investigational.
The Bottom Line
Cagrilintide vs semaglutide is amylin versus GLP-1, and investigational versus approved.
This article is for general educational purposes only. It is not medical advice and should not be used to diagnose, treat, or make decisions about any health condition or medication.
Primary Sources
- FDA labeling for semaglutide products
- Novo Nordisk cagrilintide/REDEFINE program reporting
Wellness should feel clear, personal, and supported.
Start with education, ask the right questions, and take the next step with confidence.
Get in touch →